An observational study in Tay Sachs Disease, Sandhoff Disease and Late Onset Tay Sachs Disease, sponsored by University of Minnesota. Completed at 2 sites in United States. Per ClinicalTrials.gov, last updated 2014-12-04.
Sponsored by University of Minnesota · Observational
Hypothesis: To study the natural history of Tay-Sachs disease and evaluate therapeutic interventions.
This study is intended to work in collaboration with NCT00668187 "A Natural History Study of Hexosaminidase Deficiency." Because so few patients with Tay-Sachs disease present annually, we will maximize both research projects by enrolling patients in both studies. For this present study, we will perform retrospective medical record review to gather data. Through this medical record review, we will collect biomarker analysis results, neuroimaging report data, quality-of-life questionnaire data and ophthalmology exam findings. If the subject has undergone therapy or treatment, the results will be noted.
Much has been done in the past four decades to better understand, improve diagnostic measures of, and prevent hexosaminidase deficiency diseases, yet all of them - Tay-Sachs, Sandhoff, and Late Onset Tay-Sachs (LOTS) - remain diseases without treatment. Much work remains to be done to understand and effectively treat these diseases. To date, no comprehensive assessment of the natural history of Tay-Sachs or Sandhoff has been undertaken. The information that is gathered through this study will characterize and describe the Tay-Sachs disease population as a whole, including the variability and progression of this disease. This information, in turn, will function as a point of reference against which to assess the efficacy of therapeutic interventions. Therapeutic interventions may include any treatments/therapies the subject may have undergone in the past, including hematopoietic cell transplantation, and/or the administration of miglustat, acetylcysteine, or other pharmaceutical agents; and possible future gene therapies.
24 studies on the registry are indexed under Tay-Sachs Disease; 4 are open to participants now.
Browse Tay-Sachs Disease studies →University of Minnesota is the lead sponsor of 1,216 studies on the registry; 197 are open to participants now.
Of its 136 completed or terminated interventional studies of FDA-regulated products, 95 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Any person, living or dead, who has been diagnosed with a hexosaminidase deficiency disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Any person who has been diagnosed with a hexosaminidase deficiency disease can be included in this study.
Exclusion Criteria:
The only exclusion criteria is a desire not to participate in this study.
Biomarkers
Biomarkers data to be collected include: 1. CSF (cerebro-spinal fluid) hexosaminidase A activity 2. CSF GM2-ganglioside 3. CSF protein 4. CSF chitotriosidase
Time frame: Participants will be followed for the duration of the study, an expected average of two years.
Results of Ancillary Therapies or Treatments
The results of any ancillary therapies or treatments will be noted. Such therapies or treatments may include hematopoietic cell transplantation and/or pharmacologic interventions.
Time frame: Participants will be followed for the duration of the study, an expected average of two years.
Clinical Indicators
Clinical indicators data to be collected include: 1. Cranial morphology from MRI exam reports 2. Ophthalmologic exam findings 3. Behavioral assessment and quality-of-life questionnaire responses from NCT00668187, which collaborates with the present study 4. Life-span length
Time frame: Participants will be followed for the duration of the study, an expected average of two years.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.